Urology News and Research

Latest Urology News and Research

Quality of life for men after prostate cancer treatment

Four to eight years after men undergo treatment for prostate cancer, they continue to see changes – both positive and negative – in their quality of life because of that treatment, researchers at the University of Michigan Health System and Harvard Medical School report.

11 May 2004

Risk of prostate cancer greater in men over 50 with high levels of testosterone

Men over 50 years of age with high blood levels of testosterone have an increased risk of prostate cancer, according to a study by researchers at Johns Hopkins and the National Institute on Aging. The finding throws some doubt on the safety of testosterone replacement therapy, the investigators say.

11 May 2004

New studies on the diagnosis of interstitial cystitis and the treatment of prostatitis

Antimicrobials Ineffective in Treating Chronic Prostatitis / Pelvic Pain Syndrome (CP/PPS): Though the traditional means of treating men with CP/PPS, use of antibiotics and alpha-adrenergic receptor blockers (tamsulosin and ciprofloxacin) did not lead to significant change after six and 12 weeks of treatment.

10 May 2004

Female incontinence and sexual dysfunction questions answered

Kristene Whitmore, M.D., an AUA spokesperson and director of the Pelvic Floor Institute at the Graduate Hospital in Philadelphia, will be on hand to answer reporter questions about incontinence and female sexual dysfunction on Sunday, May 9, 2004 at 3:00 p.m.

10 May 2004

Overweight post prostate cancer surgery patients have greater chance of cancer recurrence

After prostate cancer surgery, obese men are more likely than men with normal weight to have high levels of prostate specific antigen (PSA), a marker for cancer recurrence, according to a study led by Johns Hopkins researchers.

9 May 2004

Post surgery follow up by robotic physician

A new study at Johns Hopkins finds that many hospitalized patients prefer visits from their own physician to those of the physicians on duty, even when those "visits" are virtual "telerounds."

8 May 2004

British government urging doctors to dissuade unnecessary Caesarean births

Guidelines from the National Institute for Clinical Excellence say doctors should allow a woman to choose how she gives birth. They also say that women must be informed of the risks and benefits of different ways of having a baby.

1 May 2004

New bladder control device for women

An estimated one-third of all women experience it at some point and few are willing to talk about it, but urinary incontinence affects more than 15 million Americans and 1.5 million Canadians. Now, thanks to the innovative patent of a pelvic floor muscle trainer for at-home use, women can take control of the problem.

29 Apr 2004

California has set a public health goal for arsenic levels in drinking water

The California Environmental Protection Agency’s Office of Environmental Health Hazard Assessment (OEHHA) today announced the publication of a final Public Health Goal (PHG) for arsenic in drinking water.

27 Apr 2004

FDA Approves PROSCAR® Combined With Doxazosin to Reduce the Risk of Benign Prostatic Hyperplasia Symptoms

Merck & Co., Inc. today announced that the Food and Drug Administration (FDA) has approved changes to the prescribing information for PROSCAR® (finasteride) based on a landmark National Institutes of Health (NIH) study.

20 Apr 2004

Two recent innovations look set to revolutionize biomedical treatment.

The first innovation is probably the world’s first multiple drug-eluting biodegradable stent for use in any part of the body where fluid flow, including blood, is disrupted.

19 Apr 2004

Bladder cancer is the fourth most common cancer in men and the eighth most common in women

Bladder cancer is the fourth most common cancer in men and the eighth most common in women, according to the National Cancer Institute (NCI). It is expected to be diagnosed in 38,000 men and 15,000 women in the United States in 2003. Treatment is most successful when the disease is caught early.

18 Apr 2004

Men with family history of prostate cancer accurately predict higher risk

When a man is diagnosed with prostate cancer, his brothers are twice as likely to develop the disease as well, often at an earlier age.

13 Apr 2004

New online prostate calculator

A study just completed by researchers at the Josephine Ford Cancer Center has resulted in the most comprehensive long-term prostate cancer survival model available to date. An interactive version of the survival model is available online at prostatecalculator.org.

12 Apr 2004

Vitamin E appears to cut in half people's risk of bladder cancer

Getting plenty of vitamin E by eating foods like nuts and olive oil appears to cut in half people's risk of bladder cancer, the fourth leading cancer killer among men, a new study suggests.

12 Apr 2004

VCU Medical Center goes high definition

The startlingly clear images displayed by high definition televisions have attracted the attention of sports enthusiasts, movie fanatics, and video gamers. Now some surgeons at the Virginia Commonwealth University Medical Center are among the first in the country to use the technology to gain extraordinary views of the human anatomy.

12 Apr 2004

Kentucky's first robotic procedure treats prostate

Earlier this year, the University of Kentucky Hospital was the first hospital in Kentucky to perform a minimally invasive, coronary artery bypass graft using surgical robotic instruments.

12 Apr 2004

Indevus announces agreement with Pliva for overactive bladder treatment drug

Indevus Pharmaceuticals, Inc. has announced that it has entered into a co-promotion and licensing agreement with PLIVA d.d. through its specialty branded subsidiary, Odyssey Pharmaceuticals Inc., for the U.S. commercialization of SANCTURA™ (trospium chloride), under review by the U.S. Food and Drug Administration (FDA) as a treatment for overactive bladder.

10 Apr 2004

Hepatitis C wonder drug Ribasphere gets approval from FDA

The President and CEO of Three Rivers Pharmaceuticals, Donald J. Kerrish, RPh., stated, “The approval of Ribasphere™ marks a milestone in the treatment of HCV. Ribasphere™ is positioned to break down the economic barriers that have existed for the past decade in treating this chronic and potentially deadly disease.” Traditionally the cost of treatment for HCV can range from $20,000 – $25,000 annually. “Our aim is to bring affordable medicine to all individuals infected with this dreadful disease.” Mr. Kerrish continued.

8 Apr 2004

Fluorescent molecule used to examine real time chemical reactions that result in smooth-muscle contraction

Smooth muscle, found in the walls of blood vessels and in internal organs such as lungs, stomach and the bladder, contracts as the end result of a series of chemical reactions. In a new study, UT Southwestern researchers report that one set of chemical reactions resulting in the contraction of the smooth-muscle cells is augmented by a second chemical pathway that kicks in when the first pathway is limited.

5 Apr 2004